ArticleResuscitation plus2025
Serum glial fibrillary acidic protein and protein gene product 9.5 for predicting neurological outcomes in cardiac arrest patients with cortical response to somatosensory evoked potentials.
Article in Resuscitation plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Predicting neurological prognosis after cardiac arrest remains challenging. Somatosensory evoked potential N20 absence is highly specific but lacks sensitivity. Glial fibrillary acidic protein and protein gene product 9.5 are potential biomarkers for brain injury, yet their roles in cardiac arrest patients with preserved somatosensory evoked potential N20 remain underexplored. Methods: From January 2023 to December 2024, 69 cardiac arrest patients were enrolled, of whom 46 had preserved somatosensory evoked potential N20 responses. Serum glial fibrillary acidic protein, protein gene product 9.5 and neuron-specific enolase levels were measured at 72 h post-resuscitation. Patients were evaluated for neurological outcomes at 3 months using the Glasgow-Pittsburgh Classification of Cerebral Function scale. Receiver operating characteristic analysis determined biomarker thresholds for poor prognosis. Results: In patients with preserved somatosensory evoked potential N20 responses, glial fibrillary acidic protein and protein gene product 9.5 levels were significantly higher in those with poor outcomes ( Conclusions: Serum glial fibrillary acidic protein and protein gene product 9.5 could be valuable predictors of poor neurological outcomes in cardiac arrest patients with cortical response to somatosensory evoked potential, though further studies are required to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.